Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Toxicologic Pathology|May 9, 2019
Ex Vivo Gene Therapy: Graft-versus-host Disease (GVHD) in NSG™ (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) Mice Transplanted with CD34+ Human Hematopoietic Stem CellsSundeep Chandra, Patrizia Cristofori, Carlos Fonck, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 11, 2012
Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)Yan Sun, Rui Zhang, Thomas R Gadek, et al.
Clinical Therapeutics|June 24, 2015
Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy AdultsPeter E Haroldsen, Donald G Musson, Boyd Hanson, et al.
International Journal of Toxicology|June 9, 2016
Workshop Proceedings: Streamlined Development of Safety Assessment Programs Supporting Orphan/Rare Diseases-Are We There Yet?Krishna P Allamneni, Suezanne Parker, Charles A O'Neill, et al.
Toxicologic Pathology|November 3, 2023
Safety Findings of Dosing Gene Therapy Vectors in NHP With Pre-existing or Treatment-Emergent Anti-capsid AntibodiesSundeep Chandra, Brian R Long, Carlos Fonck, et al.
Pharmacology Research & Perspectives|February 19, 2015
Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphatePeter E Haroldsen, Marvin R Garovoy, Donald G Musson, et al.
Clinical Pharmacokinetics|September 20, 2014
Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndromeYulan Qi, Donald G Musson, Becky Schweighardt, et al.
Clinical Therapeutics|December 14, 2016
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension StudyBrian Long, Troy Tompkins, Celeste Decker, et al.
Molecular Genetics and Metabolism|November 10, 2009
Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimenDyane Auclair, John Finnie, Joleen White, et al.
Molecular Genetics and Metabolism|May 17, 2017
Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase)Marc Goldfinger, William L Zeile, Carley R Corado, et al.
Pageof 5